Nvidia-Backed AI Biotech Iambic Raises $150M in Nasdaq IPO Debut
Iambic Therapeutics completed a $150 million initial public offering on the Nasdaq.
The San Diego company develops cancer treatments with an artificial intelligence platform.
AI Tools Speed Up Cancer Drug Development
Its lead candidate targets HER2-altered solid tumors in early human trials.
The firm advanced that program from discovery to clinic in roughly two years.
Traditional drug discovery often takes much longer and costs more.
Investors including Nvidia and ARK backed the company since its 2019 founding.
Public Markets Test AI Biotech Model
Shares rose more than 10 percent on the first trading day.
Success here may encourage other AI-focused drug startups to list publicly.
Pharma partners could gain faster access to new compounds through similar platforms.
Founders gain liquidity while retaining capital to advance multiple programs.
Over the next 12 months clinical data will determine if the approach scales.
